A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.

Trial Profile

A Phase 2 Multi-Centre Study to Characterise the Pharmacodynamics of Vessel Dilator Peptide (VSDL) in Patients with Acute Decompensated Congestive Heart Failure to be assessed by effects on renal function.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Atrial-natriuretic-factor-prohormone-31-67 (Primary)
  • Indications Decompensated heart failure
  • Focus Pharmacodynamics
  • Acronyms CONTINUUM-HF
  • Most Recent Events

    • 04 Aug 2014 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
    • 01 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top